A drug that inhibits viral replication by inducing, viral RNA mutagenesis and is orally administered twice daily for five days.
In a randomized trial, it reduced hospitalization or death by 30% from COVID-19 as compared with placebo.
Available for COVID-19. patients at high risk for progression to severe COVID-19, and within five days of symptoms onset.
It use for adults without risk factors for progression to severe disease not using Nirmatrelvir-ritonavir or remdesvir guideline guidelines recommended against the use of molnupiravir.
Should not be used during pregnancy or in children.
Views: 4